Protecting innovation in a borderless pharma economy: The reality of globalized pharma innovation

Today’s drug development programs routinely span continents: distributed research teams, multinational clinical trial networks, and complex webs of cross-border licensing, contract manufacturing, and technology transfer. A promising scaffold discovered in Boston may be optimized in London, validated in Chennai, tested in Australia, and manufactured in Ireland before reaching patients worldwide. This creates a core tension:… The post Protecting innovation in a borderless pharma economy: The reality of globalized pharma innovation appeared first on Drug Discovery and Development.

Continue reading →